Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/22—Bridged ring systems
  • C07D221/26—Benzomorphans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/14—Antitussive agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/34—Tobacco-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents

Definitions

• the invention relates to opioid receptor binding compounds containing carboxamides that have large substitutents on the nitrogen of the carboxamide.
• the compounds are useful as analgesics, anti-diarrheal agents, anticonvulsants, anti-obesity agents, antitussives, anti- cocaine, and anti-addiction medications.
• Opiates have been the subject of intense research since the isolation of morphine in 1805, and thousands of compounds having opiate or opiate-like activity have been identified.
• Many opioid receptor-interactive compounds including those used for producing analgesia (e.g., morphine) and those used for treating drug addiction (e.g., naltrexone and cyclazocine) in humans have limited utility due to poor oral bioavailability and a very rapid clearance rate from the body.
• the compounds of the invention are therefore useful as analgesics, anti-pruritics, anti-diarrheal agents, anticonvulsants, antitussives, anorexics and as treatments for hyperalgesia, drug addiction, respiratory depression, dyskinesia, pain (including neuropathic pain), irritable bowel syndrome and gastrointestinal motility disorders.
• Drug addiction includes alcohol and nicotine addiction.
• the compounds may also be useful as immunosuppressants and antiinflammatories and for reducing ischemic damage (and cardioprotection), for improving learning and memory, and for treating urinary incontinence.
• the invention relates to compounds of formula I:
• R 1 and R 2 may form from one to three rings, said rings having optional additional substitution;
• R is chosen from hydrogen, Ci-Cs hydrocarbon, heterocyclyl, aryl and hydroxyalkyl;
• R 4 is chosen from hydrogen, hydroxyl, amino, lower alkoxy, Ci-C 2 O alkyl and Ci-
• R 5 is lower alkyl
• R 6 is lower alkyl
• R 7 is chosen from hydrogen, NR 10 R 11 and -OR 10 ; or together R 4 , R 5 , R 6 and R 7 may form from one to three rings, said rings having optional additional substitution;
• R 9 is chosen from hydrogen and lower alkyl
• R 10 and R 11 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, hydroxyl, amino or optionally substituted lower alkoxy; y is -(C(R , 10 )(R ))p- or a direct bond, wherein p is O, 1, 2, 3, 4, 5, 6, or 7; Y 2 is a direct bond or -(C(R 10 XR 11 ⁇ q-, wherein q is O, 1, 2, 3, 4 or 5; L is a direct bond or -(C(R 10 XR 11 ⁇ q-; and Cy is Ar ⁇ B-Ar 2 , wherein
• Ar 1 is absent, or an aryl or heteroaryl radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by halogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, -OR 10 , -NR 10 R 11 , -CN, -COR 10 or - COOR 10 ;
• B is a direct bond, -0-, -NR 10 , -SO 2 , or -(C(R 10 XR 1 ⁇ s-, wherein s is O, 1, 2, 3, 4 or 5;
• Ar 2 is aryl or heteroaryl radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by halogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, -OR 10 , -NR 10 R 11 , -CN, -COR 10 or -COOR 10 .
• the invention relates to a method for preparing a second compound that interacts with an opioid receptor when a first compound that interacts with an opioid receptor is known, said first compound containing a phenolic hydroxyl, said method comprising converting said phenolic hydroxyl to a residue of formula:
• the invention relates to a pharmaceutical formulation comprising a compound of formula I and a pharmaceutically acceptable carrier.
• the invention relates to a method of preventing or treating a condition or disease associated with binding opioid receptors in a patient in need thereof, comprising the step of administering to said patient a composition comprising an effective amount of a compound of formula I.
• the disease or condition to be treated or prevented is pain, pruritis, diarrhea, irritable bowel syndrome, gastrointestinal motility disorder, obesity, respiratory depression, convulsions, coughing, hyperalgesia and drug addiction.
• drug addiction encompasses heroin, cocaine, nicotine or alcohol addiction.
• the condition is pain and the composition further comprises an effective amount of an opioid.
• R 1 and R 2 may form from one to three rings, said rings having optional additional substitution;
• R 3 is chosen from hydrogen, Ci-Cg hydrocarbon, heterocyclyl, aryl and hydroxyalkyl;
• R 4 is chosen from hydrogen, hydroxyl, amino, lower alkoxy, Ci-C 2 O alkyl and Ci-
• R 5 is lower alkyl
• R is lower alkyl
• R is chosen from hydrogen, NR 10 R 11 and -OR 10 ; or together R 4 , R 5 , R 6 and R 7 may form from one to three rings, said rings having optional additional substitution;
• R 9 is chosen from hydrogen and lower alkyl
• R 10 and R 11 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, hydroxyl, amino or optionally substituted lower alkoxy; y is -(C(R , 10 )(R ))p- or a direct bond, wherein p is O, 1, 2, 3, 4, 5, 6, or 7; Y 2 is a direct bond or -(C(R 10 XR 11 ⁇ q-, wherein q is O, 1, 2, 3, 4 or 5; L is a direct bond or -(C(R 10 XR 11 ⁇ q-; and
• Cy is Ar ⁇ B-Ar 2 , wherein
• Ar 1 is absent, or an aryl or heteroaryl radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by halogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, -OR 10 , -NR 10 R 11 , -CN, -COR 10 or -
• B is a direct bond, -0-, -NR 10 , -SO 2 , or -(C(R 10 XR 1 ⁇ s-, wherein s is O, 1, 2, 3,
• Ar 2 is aryl or heteroaryl radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by halogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, -OR 10 , -NR 10 R 11 , -CN, -COR 10 or -COOR 10 .
• Subclasses of the foregoing structure include:
• R . 19 is hydrogen or lower alkyl
• R ,20 is chosen from hydrogen, lower alkyl and hydroxy(lower alkyl); or together, R 19 and R 20 form a spiro-fused carbocycle of 5 to 10 carbons;
• R 21 is hydrogen
• R 22 is chosen from hydroxyl, lower alkoxy and -NR 13 R 14 ; or together, R 21 and R 22 form a carbonyl or a vinyl substituent;
• R 13 is hydrogen or optionally substituted lower alkoxy
• R 14 is hydrogen, optionally substituted lower alkoxy, acyl or fumarate.
• the invention relates to compounds of formula II:
• Z is N. In still other embodiments, Z is CR . In further embodiments, R 10 is hydrogen. In other embodiments, R 10 is optionally substituted lower alkyl or optionally substituted lower alkoxy. In further embodiments, R 10 is methyl.
• R 1 and R 2 are each hydrogen. In other embodiments, R 1 is hydrogen and R 2 is optionally substituted lower alkyl. In still other embodiments, R 1 and R 2 are each optionally substituted lower alkyl. In some of these embodiments, R 1 and R 2 are each methyl. In yet other embodiments, R 1 is hydrogen, R 2 is -COR 10 , and R 10 , is optionally substituted lower alkoxy. In some of these embodiments, R 10 is tert-butoxy.
• R is, together with the nitrogen to which it is attached, fluorenylmethyl carbamate, tert-butyl carbamate, benzyl carbamate, acetamide, trifluoroacetamide, benzylamine, triphenylmethylamine or toluenesulfonamide.
• R 1 and R may form, together with the nitrogen to which they are attached, from one to three rings, said rings having optional additional substitution.
• R 3 is hydrogen. In other embodiments, R 3 is heterocyclyl. In still other embodiments, R 3 is hydroxyalkyl. In yet other embodiments, R 3 is Ci-Cs hydrocarbon. In further embodiments, R 3 is cyclopropyl or cyclobutyl.
• R 4 is hydrogen. In other embodiments, R 4 is hydroxyl or amino. In still other embodiments, R 4 is lower alkoxy. In yet other embodiments, R 4 is Ci- C20 alkyl or C1-C20 alkyl substituted with hydroxyl or carbonyl. In further embodiments, R 4 is methyl or ethyl.
• R 5 is lower alkyl. In some embodiments, R 5 is methyl.
• R 6 is lower alkyl. In some embodiments, R 6 is methyl.
• R 7 is hydrogen. In other embodiments, R 7 is -OR 10 . In further embodiments, R 7 is hydroxyl. In still other embodiments, R 7 is NR 10 R 11 . In further embodiments, R 7 is NH 2 , NHCH 3 or NH(CH 3 ) 2 .
• R 4 , R 5 , R 6 and R 7 together may form from one to three rings, said rings having optional additional substitution. Some representative examples are shown above in subgenera III, IV and V.
• R 9 is hydrogen. In other embodiments, R 9 is lower alkyl.
• R and R are each independently hydrogen. In other embodiments, R , 10 is optionally substituted lower alkoxy and R is hydrogen or methyl. In still other embodiments, R 10 is optionally substituted lower alkyl and R 11 is hydrogen or methyl. In yet other embodiments, R 10 is optionally substituted aryl and R 11 is hydrogen or methyl. In yet other embodiments, R 10 is hydroxyl or amino and R 11 is hydrogen or methyl. [0030] In an embodiment of the invention, y is CH 2 . In another embodiment, y is a direct bond.
• Z is CH. In other embodiments, Z is N. At the points of aattttaacchhmmeenntt ooff tthhee NNRR**RR 22 yy ggrroouupp ttoo tthhee ddii:stal aromatic ring and of the distal aromatic ring to the proximal aromatic ring, Z must be C.
• formula II has the orientation below:
• the aromatic rings of Q have a para
• each Z is equal to carbon
• R 8 , R 8a and R 9 are each hydrogen, R 5 is methyl and R 6 is methyl or ethyl.
• R 4 is hydrogen.
• R 4 is 3-oxo-5-cyclopentyl-l-pentanyl.
• R 3 is cyclopropyl.
• R 3 is hydroxycyclopropyl.
• R 3 is cyclobutyl.
• R 3 is hydrogen.
• R 3 is phenyl, furanyl or tetrahydrofuranyl.
• R 3 is vinyl or dimethylvinyl.
• -yNR > lr R>2 is attached in the para orientation (the 4-position):
• y is a direct bond.
• R 1 and R 2 are each equal to lower alkyl.
• R 1 and R 2 are each selected from hydrogen and methyl.
• R 1 and R 2 are both methyl.
• R 1 is hydrogen and R 2 is substituted alkyl.
• R 2 could be triphenylmethyl or benzyl.
• R 1 is hydrogen and R 2 is -SO2R 10 .
• R 10 is optionally substituted aryl, for instance, toluene.
• R 1 is hydrogen and R 2 is -COR 10 .
• R 10 is optionally substituted alkoxy, for instance, fluorenylmethoxy, t-butoxy, or benzyloxy. In other of these embodiments, R 10 is optionally substituted alkyl, for instance, methyl or trifluoromethyl. In some of these embodiments, R is, together with the nitrogen to which it is attached, fluorenylmethyl carbamate, tert-butyl carbamate, benzyl carbamate, acetamide, trifluoroacetamide, benzylamine, triphenylmethylamine or toluenesulfonamide. In still other embodiments, - NR 1 R 2 together form from one to three optionally substituted rings. One example is phthalimide.
• y is -CH 2 .
• R 1 and R 2 are each equal to lower alkyl.
• R 1 and R 2 are each selected from hydrogen and methyl.
• R 1 and R 2 are both methyl.
• R 1 is hydrogen and R 2 is substituted alkyl.
• R 2 could be triphenylmethyl or benzyl.
• R 1 is hydrogen and R 2 is -SO 2 R 10 .
• R 10 is optionally substituted aryl, for instance, toluene.
• R 1 is hydrogen and R 2 is -COR 10 .
• R 10 is optionally substituted alkoxy, for instance, fluorenylmethoxy, t-butoxy, or benzyloxy. In other of these embodiments, R 10 is optionally substituted alkyl, for instance, methyl or trifluoromethyl.
• R 2 is, together with the nitrogen to which it is attached, fluorenylmethyl carbamate, tert-butyl carbamate, benzyl carbamate, acetamide, trifluoroacetamide, benzylamine, triphenylmethylamine or toluenesulfonamide. In still other embodiments, -
• NNRR 11 RR 22 ttooggeetthrer form from one to three optionally substituted rings.
• One example is phthalimide.
• -VNR 1 R 2 is attached in the meta orientation (the 3 -position).
• y is a direct bond.
• R 1 and R 2 are each selected from hydrogen and methyl.
• R 1 is hydrogen and R 2 is substituted alkyl.
• R 2 could be triphenylmethyl or benzyl.
• R 1 is hydrogen and R 2 is -SO 2 R 10 .
• R 10 is optionally substituted aryl, for instance, toluene.
• R 1 is hydrogen and R 2 is -COR 10 .
• R 10 is optionally substituted alkoxy, for instance, fluorenylmethoxy, t-butoxy, or benzyloxy. In other of these embodiments, R 10 is optionally substituted alkyl, for instance, methyl or trifluoromethyl. In some of these embodiments, R is, together with the nitrogen to which it is attached, fluorenylmethyl carbamate, tert-butyl carbamate, benzyl carbamate, acetamide, trifluoroacetamide, benzylamine, triphenylmethylamine or toluenesulfonamide. In still other embodiments, - NR 1 R 2 together form from one to three optionally substituted rings. One example is phthalimide.
• R 5 and R 6 together form one ring:
• R , R and R a are each hydrogen. In other embodiments, R and R a are each hydrogen and R 4 is hydroxyl. In still other embodiments, R 4 is amino. In some of these embodiments, R 3 is hydrogen. In other embodiments, R 3 is cyclopropyl or cyclobutyl. In still other embodiments, R 3 is vinyl. In yet other embodiments, R 3 is tetrahydrofuranyl. In some embodiments, the compounds are of formula
• R 5 , R 6 and R 7 form two rings, having the structure:
• R 19 is hydrogen or lower alkyl; and R > 21 is hydrogen.
• R 20 is chosen from hydrogen, lower alkyl and hydroxy(lower alkyl)
• R 19 and R 20 together form a spiro-fused carbocycle of 5 to 10 carbons.
• R 22 is chosen from hydroxy, lower alkoxy and -NR 13 R 14 .
• R 13 is hydrogen or optionally substituted lower alkoxy.
• R 14 is hydrogen, optionally substituted lower alkoxy, acyl or fumarate.
• R 21 and R 22 together form a carbonyl or a vinyl substituent.
• the compounds are of formula
• R 4 and R 21 form a sixth ring exemplified below: .
• the sixth ring exemplified below: .
• R 4 and R 21 form a sixth ring exemplified by:
• R , 19 is hydrogen; R >20 is hydroxy(lower alkyl); and R is lower alkoxy.
• the invention relates to a method for preparing a second compound that interacts with an opioid receptor when a first compound that interacts with an opioid receptor is known.
• the method comprises converting the phenolic hydroxyl to a residue of structure:
• the residue is
• K agonists exhibit analgesic activity; compounds that are selective ⁇ agonists exhibit anti-diarrheal activity and are useful in treating dyskinesia; ⁇ antagonists and K agonists are useful in treating heroin, cocaine, alcohol and nicotine addiction; K agonists are also anti-pruritic agents and are useful in treating hyperalgesia.
• K agonists are also useful in treating retroviral infections.
• the dextrorotatory isomers of morphinans of type III above are useful as antitussives and anticonvulsants.
• Opioid receptor ligands having known high affinity are shown in the following charts.
• 7 CH 3 Cyclorphan; R-
• Registry number 189016-07-7 Registry number 189015-08-5
• Binding assays used to screen compounds are similar to those previously reported by Neumeyer et al., Design and Synthesis of Novel Dimeric Morphinan Ligands for K and ⁇ Opioid Receptors. J. Med. Chem. 2003, 46, 5162.
• Membrane protein from CHO cells that stably expressed one type of the human opioid receptor were incubated with 12 different concentrations of the compound in the presence of either 1 nM [ 3 H]U69,593 10 (K), 0.25 nM [ 3 H]DAMGO 11 ( ⁇ ) or 0.2 nM [ 3 H]naltrindole 12 ( ⁇ ) in a final volume of 1 mL of 50 mM Tris- HCl, pH 7.5 at 25°C. Incubation times of 60 min were used for [ 3 H]U69,593 and [ 3 H]DAMGO. Because of a slower association of [ 3 H]naltrindole with the receptor, a 3 h incubation was used with this radioligand.
• Samples incubated with [ 3 H]naltrindole also contained 10 mM MgCl 2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 ⁇ M naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber filters using a Brandel 48-well cell harvester. The filters were subsequently washed three times with 3 mL of cold 50 mM Tris- HCl, pH 7.5, and were counted in 2 mL Ecoscint A scintillation fluid.
• [ 35 S]GTPyS Binding Assays In a final volume of 0.5 mL, 12 different concentrations of each test compound were incubated with 15 ⁇ g (K), 10 ⁇ g ( ⁇ ) or 7.5 ⁇ g ( ⁇ ) of CHO cell membranes that stably expressed either the human K, ⁇ or ⁇ opioid receptor.
• the assay buffer consisted of 50 mM Tris-HCl, pH 7.4, 3 mM MgCl 2 , 0.2 mM EGTA, 3 ⁇ M GDP, and 100 mM NaCl.
• the final concentration of [ 35 S]GTPyS was 0.080 nM. Nonspecific binding was measured by inclusion of 10 ⁇ M GTPyS.
• Binding was initiated by the addition of the membranes. After an incubation of 60 min at 30 0 C, the samples were filtered through Schleicher & Schuell No. 32 glass fiber filters. The filters were washed three times with cold 50 mM Tris-HCl, pH 7.5, and were counted in 2 mL of Ecoscint scintillation fluid. Data are the mean E max and EC50 values ⁇ S.E.M. from at least three separate experiments, performed in triplicate. For calculation of the E max values, the basal [ 35 S]GTPyS binding was set at 0%.
• CHO membranes expressing the ⁇ opioid receptor were incubated with 12 different concentrations of the compound in the presence of 200 nM of the ⁇ agonist DAMGO.
• antagonist activity of a compound at the K opioid receptors CHO membranes expressing the K opioid receptor, were incubated with the compound in the presence of 100 nM of the K agonist U50,488.
• CHO membranes expressing the ⁇ receptor were incubated with 12 different concentrations of the test compound in the presence of 10 nM of the ⁇ -selective agonist SNC 80.
• Antinociceptive activity is evaluated by the method described in Jiang et al. [L Pharmacol. Exp. Ther. 264. 1021-1027 (1993), page 1022].
• the ED 50 'S of compounds of the invention are expected to be under 100 nmol in the mouse acetic acid writhing test when administered i.c.v., and an increase in the duration of action is expected for compounds of the invention compared to their "parents" when given by i.p. administration.
• Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. A combination would be, for example, cyclopropylmethyl.
• Lower alkyl refers to alkyl groups of from 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, s-and t-butyl, cyclobutyl and the like. Preferred alkyl groups are those of C 2 0 or below.
• Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl and the like.
• Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, or cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
• Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S.
• the aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
• aryl and heteroaryl refer to residues in which one or more rings are aromatic, but not all need be.
• Arylalkyl means an alkyl residue attached to an aryl ring. Examples are benzyl, phenethyl and the like. Heteroarylalkyl means an alkyl residue attached to a heteroaryl ring. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
• Ci to C 2 0 hydrocarbon means a linear, branched, or cyclic residue comprised of hydrogen and carbon as the only elemental constituents and includes alkyl, cycloalkyl, polycycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include benzyl, phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl.
• Heterocycle means a cycloalkyl or aryl residue in which one to two of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur. Heteroaryls form a subset of heterocycles. Examples of heterocycles that fall within the scope of the invention include pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like.
• Substituted alkyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxyloweralkyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, loweralkoxy, haloalkoxy, carboxy, carboalkoxy (also referred to as alkoxycarbonyl), alkoxycarbonylamino, carboxamido (also referred to as alkylaminocarbonyl), cyano, carbonyl, acetoxy, nitro, amino, alkylamino, dialkylamino, mercapto, alkylthio, sulfoxide, sulfone, sulfonylamino, acylamino,
• Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
• the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
• salts i.e. cationic species. Therefore they will always be presented as salts, and the term "pharmaceutically acceptable salt” refers to salts whose counter ion (anion) derives from pharmaceutically acceptable nontoxic acids including inorganic acids, organic acids and water (which formally furnishes the hydroxide anion).
• Suitable pharmaceutically acceptable anions for the compounds of the present invention include hydroxide, acetate, benzenesulfonate (besylate), benzoate, bicarbonate, bisulfate, carbonate, camphorsulfonate, citrate, ethanesulfonate, fumarate, gluconate, glutamate, glycolate, bromide, chloride, isethionate, lactate, maleate, malate, mandelate, methanesulfonate, mucate, nitrate, pamoate, pantothenate, phosphate, succinate, sulfate, tartrate, trifluoroacetate, p-toluenesulfonate, acetamidobenzoate, adipate, alginate, aminosalicylate, anhydromethylenecitrate, ascorbate, aspartate, calcium edetate, camphorate, camsylate, caprate, caproate, caprylate, cin
• the desired salt may be obtained by ion exchange of whatever counter ion is obtained in the synthesis of the quat.
• pharmaceutically acceptable counter ions will be preferred for preparing pharmaceutical formulations, other anions are quite acceptable as synthetic intermediates.
• X may be pharmaceutically undesirable anions, such as iodide, oxalate, trifluoromethanesulfonate and the like, when such salts are chemical intermediates.
• the compounds of the invention are bisquats, one may employ as counter ions either two monoanionic species (e.g. CI 2 ) or a single dianionic species (e.g. fumarate).
• oligoanionic species and make salts having appropriate ratios of quat to counterion such as (quafb citrates. These would be obvious equivalents.
• a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
• the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
• Proton NMR spectra and in certain cases 13 C NMR were obtained on a Varian Unity- 300 or 500 NMR spectrometer with tetramethylsilane as an internal reference for samples dissolved in CDCI3. Samples dissolved in CD 3 OD and were referenced to the solvent. Proton NMR multiplicity data are denoted by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublets), and br (broad). Coupling constants are in hertz. Direct insertion probe chemical ionization mass spectral data were obtained on a Shimadzu GC- 17A GC-MS mass spectrometer.
• Direct infusion electrospray ionization (in positively charged ion mode) mass spectral data were obtained on an Agilent 1100 series LC/MSD system (Germany). Melting points were determined on a Meltemp capillary melting point apparatus and were uncorrected. Infrared spectral data were obtained on a Perkin-Elmer Paragon 1000 FT-IR spectrophotometer. Optical rotation data was obtained from a Perkin-Elmer 241 polarimeter. The assigned structure of all test compounds and intermediates were consistent with the data.
• the following reagent was purchased from Trans World Chemicals: 2-(4-biphenyl ethylamine).
• the following reagents were purchased from Strem Chemicals, Incorporated: l,l '-bis(diphenyl- phosphino)ferrocene (dppf) and dichloro[l,l '-bis(diphenylphosphino)-ferrocene]palladium (II) dichloromethane adduct [PdCl2(dppf)].
• Pyridine was distilled from KOH. DMF and DMSO were distilled over CaH 2 under reduced pressure.
• Silica gel (Bodman Industries, ICN SiliTech 2-63 D 6OA, 230-400 Mesh) was used for all flash chromatography. Amines were purchased from Aldrich Chemical Company and used as received unless otherwise indicated. Toluene and Et 2 O were distilled from sodium metal. THF was distilled from sodium/benzophenone ketyl. Pyridine was distilled from KOH. Methylene chloride was distilled from CaH 2 . DMF and DMSO were distilled from CaH 2 under reduced pressure. Methanol was dried over 3 ⁇ molecular sieves prior to use. Silica gel (Bodman Industries, ICN SiliTech 2-63 D 6OA, 230-400 Mesh) was used for flash column chromatography.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Addiction (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Pulmonology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Rheumatology (AREA)
• Child & Adolescent Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Other In-Based Heterocyclic Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=41137538

Family Applications (1)

Country Status (7)

Cited By (8)

Families Citing this family (1)

Citations (1)

Family Cites Families (3)

• 2009
  • 2009-07-21 CA CA2731429A patent/CA2731429C/en active Active
  • 2009-07-21 ES ES09790652.3T patent/ES2534055T3/es active Active
  • 2009-07-21 WO PCT/US2009/051200 patent/WO2010011619A1/en not_active Ceased
  • 2009-07-21 EP EP20090790652 patent/EP2318372B9/en active Active
  • 2009-07-21 JP JP2011520127A patent/JP5727374B2/ja active Active
  • 2009-07-21 US US12/506,354 patent/US20100190817A1/en not_active Abandoned
  • 2009-07-21 AU AU2009274147A patent/AU2009274147B2/en not_active Ceased
• 2014
  • 2014-10-03 JP JP2014204620A patent/JP2015044819A/ja active Pending

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events